Coherus Oncology enters ATM equity sales agreement for up to $50 million common stock offering

Shares will be offered under the company’s existing Form S-3 shelf registration statement, with a prospectus supplement dated Aug. 28, 2026.

Net proceeds are earmarked for general corporate purposes, including working capital.

Coherus Oncology entered an at-the-market sales agreement with Leerink Partners to sell up to $50 million of common stock.

Sales may occur from time to time through the agent, acting as agent or principal, under Rule 415.

Leerink is eligible for commissions of up to 3% of gross proceeds; either party can terminate the agreement with 10 days’ notice.